Abstract
Peripheral arterial disease (PAD) affects a large number of individuals over the age of 55 years old, and data from studies has shown a relationship between inflammation, and PAD. Many researchers have not only focused on the role played by inflammatory biomarkers and the progression of PAD, but also on the efficiency of biomarkers in monitoring medical, surgical and interventional strategies in PAD patients. In this review, Authors aim to demonstrate that biomarkers play a key role in the pathophysiology of PAD, and consequently they could be screened to highlight individuals showing these crucial pathophysiological signs. Based on a large debate about phlogosis, it is now considered to be a relevant objective in reducing the prevalence and consequences of atherosclerotic diseases such as PAD. Finally, efforts must be made towards addressing this very important objective, and consequently a greater number of studies need to be made in combatting phlogosis, especially among PAD patients.
Keywords: Peripheral arterial disease, phlogosis, biomarkers, medical therapy, inflammation, inflammatory biomarkers, atherosclerotic diseases, T-lymphocytes, C-reactive protein (CRP), Metalloproteinase (MMPS)
Current Pharmaceutical Design
Title:Inflammation in Peripheral Arterial Disease (PAD)
Volume: 18 Issue: 28
Author(s): Salvatore Santo Signorelli, Massimiliano Anzaldi and Valerio Fiore
Affiliation:
Keywords: Peripheral arterial disease, phlogosis, biomarkers, medical therapy, inflammation, inflammatory biomarkers, atherosclerotic diseases, T-lymphocytes, C-reactive protein (CRP), Metalloproteinase (MMPS)
Abstract: Peripheral arterial disease (PAD) affects a large number of individuals over the age of 55 years old, and data from studies has shown a relationship between inflammation, and PAD. Many researchers have not only focused on the role played by inflammatory biomarkers and the progression of PAD, but also on the efficiency of biomarkers in monitoring medical, surgical and interventional strategies in PAD patients. In this review, Authors aim to demonstrate that biomarkers play a key role in the pathophysiology of PAD, and consequently they could be screened to highlight individuals showing these crucial pathophysiological signs. Based on a large debate about phlogosis, it is now considered to be a relevant objective in reducing the prevalence and consequences of atherosclerotic diseases such as PAD. Finally, efforts must be made towards addressing this very important objective, and consequently a greater number of studies need to be made in combatting phlogosis, especially among PAD patients.
Export Options
About this article
Cite this article as:
Santo Signorelli Salvatore, Anzaldi Massimiliano and Fiore Valerio, Inflammation in Peripheral Arterial Disease (PAD), Current Pharmaceutical Design 2012; 18 (28) . https://dx.doi.org/10.2174/138161212802481273
DOI https://dx.doi.org/10.2174/138161212802481273 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Different Lifestyles in Young Women From Urban and Rural Areas May Explain Different Cardiovascular Risk
Vascular Disease Prevention (Discontinued) The Promises and Challenges of the Use of Genomics in the Prescription of Exercise in Hypertension
Current Hypertension Reviews Editorial: Do Some Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1 RA) Reduce Macrovascular Complications of Type 2 Diabetes Mellitus? (A Commentary on the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) Trial)
Current Vascular Pharmacology High Prevalence of AH in HIV Patients on ART, in Bahia, Brazil
Current HIV Research Aptamers in Drug Design: An Emerging Weapon to Fight a Losing Battle
Current Drug Targets microRNA in Chondrogenesis, Cartilage and Osteoarthritis
Current Rheumatology Reviews Prevention of Myocardial Damage During Coronary Intervention
Cardiovascular & Hematological Disorders-Drug Targets Conduction Disorders: The Value of Surface ECG
Current Cardiology Reviews Biomarkers Determining Cardiovascular Risk in Patients with Kidney Disease
Current Medicinal Chemistry Nutraceuticals for Metabolic Syndrome Management: From Laboratory to Benchside
Current Vascular Pharmacology Potential of Flavonoids as Anti-inflammatory Agents: Modulation of Pro- Inflammatory Gene Expression and Signal Transduction Pathways
Current Drug Metabolism Perspectives on New Synthetic Curcumin Analogs and their Potential Anticancer Properties
Current Pharmaceutical Design Actions of Selected Cardiovascular Hormones on Arterial Stiffness and Wave Reflections
Current Pharmaceutical Design Inspired Nitric Oxide and Modulation of Oxidative Stress During Cardiac Surgery
Current Drug Safety Pharmacogenomic Research in South Africa: Lessons Learned and Future Opportunities in the Rainbow Nation
Current Pharmacogenomics and Personalized Medicine Drugs Used to Treat Parkinsons Disease, Present Status and Future Directions
CNS & Neurological Disorders - Drug Targets Ghrelin as a Neuroprotective and Palliative Agent in Alzheimer's and Parkinson's Disease
Current Pharmaceutical Design Insights into Oxidative Stress: The Isoprostanes
Current Medicinal Chemistry Metabolic Syndrome and Cardiometabolic Risk Factors
Current Vascular Pharmacology Advanced Drug Delivery of N-Acetylcarnosine (N-Acetyl-beta-alanyl-Lhistidine), Carcinine (Beta-alanylhistamine) and L-carnosine (Beta-alanyl- L-histidine) in Targeting Peptide Compounds as Pharmacological Chaperones for Use in Tissue Engineering, Human Disease Management and Therapy: From in vitro to the Clinic
Recent Patents on Drug Delivery & Formulation